The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held
on 26 September 2018 included commitments by Member States to four new global targets.3
One of
these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018–2022. The
ap...
About one fourth of the world’s population is estimated to be infected with the tuberculosis (TB) bacterium, and about 5–10% of those infected develop active TB disease in their lifetime. The risk for active TB disease after infection depends on several factors, the most important being the person’...
Las cepas del bacilo tuberculoso con farmacorresistencia (TB-DR) son más difíciles de tratar que las
farmacosensibles y amenazan el progreso mundial hacia los objetivos establecidos por la Estrategia Fin de
la TB, de la Organización Mundial de la Salud (OMS). Por lo tanto, existe una necesidad imperio...
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services ...
The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
Tuberculosis/drug therapy,
Tuberculosis, Multidrug-Resistant/drug therapy,
Antitubercular Agents/administration & dosage,
Clinical Protocols,
Treatment Outcome,
Fluoroquinolones/administration & dosage,
Rifampin/administration & dosage,
Isoniazid/administration & dosage,
Pyrazinamide/administration & dosage,
Ethambutol/administration & dosage
Nahid, P;
Dorman, SE;
Alipanah, N;
Barry, PM;
Brozek, JL;
Cattamanchi, A;
Chaisson, LH;
Chaisson, RE;
Daley, CL;
Grzemska, M;
Higashi, JM;
Ho, CS;
Ho, CS;
Hopewell, PC;
Keshavjee, SA;
Lienhardt, C;
Menzies, R;
Merrifield, C;
Narita, M;
O'Brien, R;
Peloquin, CA;
Raftery, A;
Saukkonen, J;
Schaaf, HS;
Sotgiu, G;
Starke, JR;
Migliori, GB;
Vernon, A.
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tube...
Ren, CL;
Esther CR, Jr;
Debley, JS;
Sockrider, M;
Yilmaz, O;
Amin, N;
Bazzy-Asaad, A;
Davis, SD;
Durand, M;
Ewig, JM;
Yuksel, H;
Lombardi, E;
Noah, TL;
Radford, P;
Ranganathan, S;
Teper, A;
Weinberger, M;
Brozek, J;
Wilson, KC.
"BACKGROUND:
Infantile wheezing is a common problem, but there are no guidelines for the evaluation of infants with recurrent or persistent wheezing that is not relieved or prevented by standard therapies.
METHODS:
An American Thoracic Society-sanctioned guideline development committee selected clinical...
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...
In 2011 WHO conditionally recommended the use of at least 36 months of isoniazid preventive therapy (IPT) (as a proxy for lifelong or continuous treatment) for people living with HIV in high TB-prevalence and transmission settings. The evidence of the benefits and harms of 36-month IPT compared to 6-mont...
This Guideline outlines the purpose and the target audience of the second edition of Guidance for national tuberculosis programmes on the management of tuberculosis in children. It discusses the difference between TB in children and adolescents and TB in adults and provides an estimate of the burden of c...
